Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Alumis Inc. Common StockNASDAQ: ALMS

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $85.34M fell 21.5% year over year, behind the -8.7% change in trailing-twelve-month research & development. Sequentially, it rose 5.8% from the prior quarter. Over 3 fiscal years it compounded at +56.3% a year.

Context

  • Research & development amounted to 1605.0% of revenue in FY2025.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -21.5% toward the trailing-twelve-month pace of -8.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$85.34M+5.8% QoQ
Last fiscal yearDec 2025
$386M+45.4% YoY
LTMJun 2026
$346.63M-8.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.5%——
1 year+45.4%——
3-year CAGR+56.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
386M USD
Year-over-year change
+45.4%
3-year CAGR
+56.3%

Research & Development vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.7% is the 7th highest of 10, against a peer median of +41.7%.
  • Research & development amounts to 4685.4% of revenue for ALMS, versus a peer median of 677.9%.
ALMS Competitors
Research & Development for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$346.63M USD-8.7%+56.3%4685.4%
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M USD-23.4%+15.3%55.4%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$71.8M USD+27.7%+16.5%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€39.31M EUR+49.4%——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$36.54M USD+41.7%-17.9%12.2%
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$20.65M USD-58.3%-18.4%—
TLSATiziana Life Sciences LtdFY2025$10.28M USD+96.6%-13.6%—
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ALMS) —+41.7%-12.0%677.9%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00024.05M
Cost of Revenue250K03.15M3.5M
Gross Profit(250K)0(3.15M)20.55M
Gross Margin———85.5%
Research & Development101.05M137.68M265.55M386M
Selling, General & Admin12.55M20.5M35.2M91.86M
Operating Expenses113.6M158.17M297.6M447.76M
Depreciation & Amortization250K1.28M3.15M3.5M
EBITDA(111.68M)(153.71M)(291.08M)(248.39M)
EBITDA Margin———-1032.8%
Operating Income(113.85M)(158.17M)(300.75M)(427.2M)
Operating Margin———-1776.3%
Interest Income1.99M3.37M12.02M14.18M
Interest Expense0000
Other Income / Expenses1.92M3.18M6.52M175.32M
Income Before Tax(111.93M)(154.99M)(294.23M)(251.89M)
Pre-Tax Margin———-1047.3%
Income Tax Expense000(8.56M)
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Net Margin———-1011.7%
EPS (Basic)(14.93)(2.99)(10.38)(2.32)
EPS (Diluted)(14.93)(2.99)(10.38)(2.32)
Weighted Avg Shares7.5M51.84M28.34M850.3M
Weighted Avg Shares (Diluted)7.5M51.84M28.34M850.3M

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.